Review Article
The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention
Table 4
Drug suspension for cancer patients; it must be agreed upon with the oncologist and performed according to the table.
| | Drug holiday in cancer patients | | Active pharmaceutical ingredient | Last administration | Resume treatment |
| | Bisphosphonate (AR) | At least 1 week before | 4–6 weeks after | | Denosumab (AR) | At least 1 week before | 4–6 weeks after | | Bevacizumab (AA) | At least 6-7 weeks before | 4–6 weeks after | | Sunitinib (AA) | At least 1 week before | 4–6 weeks after | | Everolimus (AA) | At least 1 week before | 4–6 weeks after |
|
|
